Liang Chen

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 14

Top Topics

Advanced Non Small Cell Lung Cancer

Epidermal Growth Factor Receptor

Top Venues

The Journal of experimental medicine

Science advances

EMBO molecular medicine

Cell & bioscience

This page only lists publications with an associated author ORCID identifier.

Publications

Zhen Qin, Meiting Yue, Shijie Tang, Feng-Ying Wu, Honghua Sun, Yuan Li, Yong-Chang Zhang, Hiroki Izumi, Hsin-Yi Huang, Wanying Wang, Yun Xue, Xinyuan Tong, Shunta Mori, Tetsuro Taki, Koichi Goto, Yujuan Jin, Fei Li, Fu-Ming Li, Yijun Gao, Zhaoyuan Fang, Yisheng Fang, Liang Hu, Xiumin Yan, Guo-Liang Xu, Haiquan Chen, Susumu S Kobayashi, Andrea Ventura, Kwok-Kin Wong, Xueliang Zhu, Liang Chen, Shengxiang Ren, Luo-Nan Chen, Hongbin Ji
EML4-ALK fusions drive lung adeno-to-squamous transition through JAK-STAT activation. The Journal of experimental medicine 221 (3) (2024)
Zhen Qin, Meiting Yue, Shijie Tang, Feng-Ying Wu, Honghua Sun, Yuan Li, Yong-Chang Zhang, Hiroki Izumi, Hsin-Yi Huang, Wanying Wang, Yun Xue, Xinyuan Tong, Shunta Mori, Tetsuro Taki, Koichi Goto, Yujuan Jin, Fei Li, Fu-Ming Li, Yijun Gao, Zhaoyuan Fang, Yisheng Fang, Liang Hu, Xiumin Yan, Guo-Liang Xu, Haiquan Chen, Susumu S Kobayashi, Andrea Ventura, Kwok-Kin Wong, Xueliang Zhu, Liang Chen, Shengxiang Ren, Luo-Nan Chen, Hongbin Ji
EML4-ALK fusions drive lung adeno-to-squamous transition through JAK-STAT activation. The Journal of experimental medicine 221 (3) (2024)
Zhen Qin, Meiting Yue, Shijie Tang, Feng-Ying Wu, Honghua Sun, Yuan Li, Yong-Chang Zhang, Hiroki Izumi, Hsin-Yi Huang, Wanying Wang, Yun Xue, Xinyuan Tong, Shunta Mori, Tetsuro Taki, Koichi Goto, Yujuan Jin, Fei Li, Fu-Ming Li, Yijun Gao, Zhaoyuan Fang, Yisheng Fang, Liang Hu, Xiumin Yan, Guo-Liang Xu, Haiquan Chen, Susumu S Kobayashi, Andrea Ventura, Kwok-Kin Wong, Xueliang Zhu, Liang Chen, Shengxiang Ren, Luo-Nan Chen, Hongbin Ji
EML4-ALK fusions drive lung adeno-to-squamous transition through JAK-STAT activation. The Journal of experimental medicine 221 (3) (2024)
Lu Liu, Fenghua Chen, Shan Li, Tong Yang, ShuZhen Chen, Yang Zhou, Zejian Lin, Guandi Zeng, Pengju Feng, Hong-Bing Shu, Qian Zhou, Ke Ding, Liang Chen
Human/mouse CD137 agonist, JNU-0921, effectively shrinks tumors through enhancing the cytotoxicity of CD8 + T cells in cis and in trans. Science advances 10 (34) (2024)
Lu Liu, Fenghua Chen, Shan Li, Tong Yang, ShuZhen Chen, Yang Zhou, Zejian Lin, Guandi Zeng, Pengju Feng, Hong-Bing Shu, Qian Zhou, Ke Ding, Liang Chen
Human/mouse CD137 agonist, JNU-0921, effectively shrinks tumors through enhancing the cytotoxicity of CD8 + T cells in cis and in trans. Science advances 10 (34) (2024)
Zhen Qin, Meiting Yue, Shijie Tang, Feng-Ying Wu, Honghua Sun, Yuan Li, Yong-Chang Zhang, Hiroki Izumi, Hsin-Yi Huang, Wanying Wang, Yun Xue, Xinyuan Tong, Shunta Mori, Tetsuro Taki, Koichi Goto, Yujuan Jin, Fei Li, Fu-Ming Li, Yijun Gao, Zhaoyuan Fang, Yisheng Fang, Liang Hu, Xiumin Yan, Guo-Liang Xu, Haiquan Chen, Susumu S Kobayashi, Andrea Ventura, Kwok-Kin Wong, Xueliang Zhu, Liang Chen, Shengxiang Ren, Luo-Nan Chen, Hongbin Ji
EML4-ALK fusions drive lung adeno-to-squamous transition through JAK-STAT activation. The Journal of experimental medicine 221 (3) (2024)
Lu Liu, Fenghua Chen, Shan Li, Tong Yang, ShuZhen Chen, Yang Zhou, Zejian Lin, Guandi Zeng, Pengju Feng, Hong-Bing Shu, Qian Zhou, Ke Ding, Liang Chen
Human/mouse CD137 agonist, JNU-0921, effectively shrinks tumors through enhancing the cytotoxicity of CD8 + T cells in cis and in trans. Science advances 10 (34) (2024)
Zhen Qin, Meiting Yue, Shijie Tang, Feng-Ying Wu, Honghua Sun, Yuan Li, Yong-Chang Zhang, Hiroki Izumi, Hsin-Yi Huang, Wanying Wang, Yun Xue, Xinyuan Tong, Shunta Mori, Tetsuro Taki, Koichi Goto, Yujuan Jin, Fei Li, Fu-Ming Li, Yijun Gao, Zhaoyuan Fang, Yisheng Fang, Liang Hu, Xiumin Yan, Guo-Liang Xu, Haiquan Chen, Susumu S Kobayashi, Andrea Ventura, Kwok-Kin Wong, Xueliang Zhu, Liang Chen, Shengxiang Ren, Luo-Nan Chen, Hongbin Ji
EML4-ALK fusions drive lung adeno-to-squamous transition through JAK-STAT activation. The Journal of experimental medicine 221 (3) (2024)
Lu Liu, Yuxi Lei, Zongyao Zheng, Xingang Zhou, Shuzhen Chen, Guandi Zeng, Lei Yu, Peng Wang, Liang Chen
6-Mercaptopurine potently inhibits recruitment of SHP2 by phosphorylated PD-1 to inhibit PD-1 signalling and enhance T cell function. Immunology (2023)
Lu Liu, Yuxi Lei, Wensheng Chen, Qian Zhou, Zongyao Zheng, Guandi Zeng, Wanting Liu, Pengju Feng, Zhiyi Zhang, Lei Yu, Liang Chen
In vivo genome-wide CRISPR screening identifies ZNF24 as a negative NF-κB modulator in lung cancer. Cell & bioscience 12 (1) (2022)
Qian Zhou, Jinxia Liang, Tong Yang, Jin Liu, Bo Li, Yingchang Li, Zhenzhen Fan, Weida Wang, Wensheng Chen, Sujing Yuan, Meng Xu, Qigui Xu, Zhidong Luan, Zhongjun Xia, Penghui Zhou, Yadong Huang, Liang Chen
Carfilzomib modulates tumor microenvironment to potentiate immune checkpoint therapy for cancer. EMBO molecular medicine 14 (1) (2021)
Yue Lu, Zhenzhen Fan, Su-Jie Zhu, Xiaoxing Huang, Zhongji Zhuang, Yunzhan Li, Zhou Deng, Lei Gao, Xuehui Hong, Ting Zhang, Li Li, Xihuan Sun, Wei Huang, Jingfang Zhang, Yan Liu, Baoding Zhang, Jie Jiang, Fu Gui, Zheng Wang, Qiyuan Li, Siyang Song, Xin Huang, Qiao Wu, Lanfen Chen, Dawang Zhou, Jianming Zhang, Cai-Hong Yun, Liang Chen, Xianming Deng
A new ALK inhibitor overcomes resistance to first- and second-generation inhibitors in NSCLC. EMBO molecular medicine (2021)
Bo Li, Jinxia Liang, Feng Lu, Guandi Zeng, Jindao Zhang, Yinxing Ma, Peng Liu, Qin Wang, Qian Zhou, Liang Chen
Discovery of Novel Inhibitor for WNT/β-Catenin Pathway by Tankyrase 1/2 Structure-Based Virtual Screening. Molecules (Basel, Switzerland) 25 (7) (2020)
Zhenzhen Fan, Yahui Tian, Zhipeng Chen, Lu Liu, Qian Zhou, Jingjing He, James Coleman, Changjiang Dong, Nan Li, Junqi Huang, Chenqi Xu, Zhimin Zhang, Song Gao, Penghui Zhou, Ke Ding, Liang Chen
Blocking interaction between SHP2 and PD-1 denotes a novel opportunity for developing PD-1 inhibitors. EMBO molecular medicine 12 (6) (2020)